|BETT||GLENNA C L BETT||1|
Phase 1 STTR
DESCRIPTION (provided by applicant): As part of the FDA approval process for novel therapeutic drugs, safety screening demonstrating that the new drug does not have deleterious effects on the human cardiac action potential is required. Healthy human heart cells are not available for such preclinical drug testing. There is currently no consensus ...